-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from 2012 to 2023.
- Revance Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities for the quarter ending March 31, 2024 was -$31.7M, a 133% decline year-over-year.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2023 was $110M.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2022 was -$139M, a 368% decline from 2021.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2021 was -$29.7M, a 345% decline from 2020.
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Growth (%)